Analysis of Inventory
Inventory Disclosure
Cigna Group, balance sheet: inventory
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prescription drugs and medical supplies | 6,692) | 5,645) | 4,777) | 3,722) | 3,165) | ||||||
| Inventories | 6,692) | 5,645) | 4,777) | 3,722) | 3,165) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The total inventory value exhibits a consistent and significant upward trajectory over the five-year period from 2020 to 2024, indicating a steady expansion of held assets.
- Inventory Composition
- The inventory is composed exclusively of prescription drugs and medical supplies. The identical values reported for both the specific category and total inventories indicate that no other inventory types are maintained by the organization.
- Growth Magnitude and Trend
- A sustained increase in inventory levels is observed, rising from US$ 3,165 million at the end of 2020 to US$ 6,692 million by the end of 2024. This represents an overall increase of approximately 111.4% over the analyzed period.
- Annual Growth Dynamics
- The growth rate peaked between 2021 and 2022, with a substantial increase of approximately 28.3%. Following this peak, the growth stabilized, with an increase of 18.2% in 2023 and 18.6% in 2024, demonstrating a consistent expansion of the pharmaceutical and medical supply stockpile.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?